A method of identifying falsified vaccines without opening the vaccine vial has been developed by researchers at the University of Oxford. The approach analyses the vaccine vial label and its ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

BECKLEY, W.Va. — An FBI chemist who tested a vial found in accused murderer Natalie Cochran’s refrigerator after the death of her husband testified Friday what was in the vial was consistent ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

Support from readers like you keeps The Journal open. You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to ...

While there is plenty of excitement about the new gene editing treatment, Casgevy, some in the sickle-cell community say they have been let down before and worry about being let down again.

LONDON, January 31, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to ...

LONDON--(BUSINESS WIRE)--Jan. 31, 2025-- Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the ...

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD ...

According to the firm, the reimbursement agreement comes as the National Institute for Health and Care Excellence or NICE issues positive guidance recommending CASGEVY's use in the NHS.

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy. The ...